Matthew D. Hall

This paper identifies a synergistic combination of CDK4/6 and PI3K inhibitors that shows strong anti-Ewing sarcoma activity and improved survival in a xenograft model.

The paper identifies ampyrone as a direct activator of human tyrosinase, showing increased catalytic activity and melanin synthesis in melanocytes and skin cultures, suggesting potential therapeutic use for hypopigmentation disorders.

This study identifies ADC payloads transported by ABC transporters, showing potential for drug resistance and suggesting payload selection to avoid this.

The paper identifies two novel GPR17 antagonists through high-throughput screening that selectively inhibit GPR17 signaling and enhance GLP-1 secretion, offering potential for diabetes and obesity treatment.

This study creates a biliary tract cancer cell line atlas using multi-omics data to identify molecular subtypes and therapeutic targets.

The paper creates a comprehensive small molecule library for pain and opioid use disorder with physical samples and an AI-driven platform for drug discovery.

This paper develops potent humanized nanobodies against SARS-CoV-2 spike protein, showing effectiveness against the Alpha variant and providing structural insights into their neutralization mechanism.

The paper presents a workflow for integrating diverse datasets to build a network pharmacology resource for COVID-19 research, resulting in a Neo4j graph database named Neo4COVID19.

MICHA is a pipeline that FAIRifies chemosensitivity assays by automatically annotating compounds, samples, reagents, and data processing methods, enabling interoperable and reusable drug screening data.

This study identifies novel TMPRSS2 inhibitors through virtual screening and experimental validation, offering potential drug candidates for COVID-19 treatment.

This study identifies five small molecule inhibitors of NSD2 through high-throughput screening and validates their activity in cell-based assays.